DNTH Dianthus Therapeutics PE ratio, current and historical analysis
The current P/E ratio of DNTH cannot be calculated, as the latest EPS of -$2.55 is negative. The most recent PE ratio recorded for Dianthus Therapeutics was 3.82 in September 2024.
DNTH PE ratio history
How has DNTH's PE ratio performed in the past
Today
N/A
Average
N/A
Median
N/A
Minimum
N/A
Maximum
N/A
Dianthus Therapeutics PE ratio by year
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2024 | N/A | N/A | $21.8 | -$2.55 |
| 2023 | N/A | N/A | $10.4 | -$8.45 |
| 2022 | N/A | N/A | $6.32 | -$32.57 |
| 2021 | N/A | N/A | $70.88 | -$20.64 |
| 2020 | N/A | N/A | $125.44 | -$27.36 |
| 2019 | N/A | N/A | $242.56 | -$33.12 |
| 2018 | N/A | N/A | $91.2 | -$50.08 |
| 2017 | N/A | N/A | N/A | -$305.92 |
| 2016 | N/A | N/A | N/A | -$1,042.4 |
Dianthus Therapeutics PE ratio by quarter (TTM)
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Dec 2024 | N/A | N/A | $21.8 | -$2.55 |
| Sep 2024 | 3.82 | -39.17% | $27.38 | $7.16 |
| Jun 2024 | 6.28 | N/A | $25.88 | $4.12 |
| Mar 2024 | N/A | N/A | $30 | -$8.1 |
| Dec 2023 | N/A | N/A | $10.4 | -$8.45 |
| Sep 2023 | N/A | N/A | $13.67 | -$36.18 |
| Jun 2023 | N/A | N/A | $12.13 | -$41.3 |
| Mar 2023 | N/A | N/A | $12.72 | -$33.21 |
| Dec 2022 | N/A | N/A | $6.32 | -$32.57 |
| Sep 2022 | N/A | N/A | $22.56 | -$24.9 |
| Jun 2022 | N/A | N/A | $19.2 | -$20.8 |
| Mar 2022 | N/A | N/A | $46.4 | -$21.28 |
| Dec 2021 | N/A | N/A | $70.88 | -$20.64 |
| Sep 2021 | N/A | N/A | $116.48 | -$21.6 |
| Jun 2021 | N/A | N/A | $156.48 | -$22.72 |
DNTH average PE ratio chart
What is the average PE ratio of DNTH for the past years
3-year avg
N/A
5-year avg
N/A
10-year avg
N/A
15-year avg
N/A
DNTH PE vs peers
What is DNTH's PE ratio compared to its peers
| Stock name | PE ratio | Market cap |
|---|---|---|
| OLMA Olema Pharmaceuticals Inc | N/A | $230.28M |
| OMER Omeros Corp | N/A | $432M |
| ONVO Organovo Holdings Inc | N/A | $3.16M |
| ORIC Oric Pharmaceuticals Inc | N/A | $369.69M |
| ORMP Oramed Pharmaceuticals Inc | N/A | $89.46M |
| DNTH Dianthus Therapeutics Inc | N/A | $530.07M |
Frequently asked questions
What is Dianthus Therapeutics's PE ratio?
The current price to earnings ratio of DNTH cannot be determined, as its EPS of -$2.55 is negative.
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from 
and Sharadar.